Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.64 USD | +1.52% | +3.41% | -1.42% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 11 | Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.42% | 6.87B | |
-1.65% | 105B | |
+3.66% | 97.5B | |
+1.86% | 22.19B | |
-16.28% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-21.22% | 14.52B | |
+5.02% | 14.09B | |
+21.88% | 10.99B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis Starts Phase 3 Trial of Zanzalintinib-Nivolumab Combination in Advanced Non-Clear Cell Kidney Cancer